FrançaisEnglish

Érudit | Dépôt de documents >
CIRPÉE - Centre interuniversitaire sur le risque, les politiques économiques et l'emploi >
Cahiers de recherche du CIRPÉE >

Please use this identifier to cite or link to this item:

https://depot.erudit.org/id/003241dd

Title: Health and Acces Effects of New Drugs: Combining Experimental and Non-Experimental Data
Authors: Michaud, Pierre-Carl
Lakdawalla, Darius
Goldman, Dana
Sood, Neeraj
Cong, Ze
Keywords: Pharmaceutical innovation
Effectiveness
Cost-benefit analysis
Cancer
Issue Date: 2010-09
Series/Report no.: Cahiers du CIRPÉE;10-38
Abstract: We propose to combine clinical trial and estimates of behavioral responses in the population to quantify the value of new drug innovations when such values cannot be obtained by randomized experiments alone. New drugs are seen as having two distinct effects on patients. First, they can provide better outcomes for patients currently under treatment, due to better clinical efficacy. Second, they can also provide treatment access to more patients, perhaps by reducing side effects or expanding treatment. We compare these “clinical” and “access” effects using claims data, data on the arrival rate of new drugs, and the clinical trials literature on the effectiveness of these drugs. We find that the effect of new drug introductions on the number of patients treated accounts for a substantial majority of the value created by new drugs.
URI: https://depot.erudit.org/id/003241dd
Appears in Collections:Cahiers de recherche du CIRPÉE

Files in This Item:

CIRPEE10-38.pdf, (Adobe PDF ; 351.3 kB)

Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

 

About Érudit | Subscriptions | RSS | Terms of Use | Contact us |

Consortium Érudit ©  2016